Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Sun pharma - The Untold Story

Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid

Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries. This action follows Sun Pharma's proposed acquisition of US-based Organon & Co. The deal is expected to significantly bolster Sun Pharma's business position and revenue base. Organon will contribute substantially to the group's earnings after the acquisition. This…

The Economic Times

Stocks in news: Swiggy, Adani Ports, IDFC First Bank, Hexaware Technologies and Sun Pharma

Indian markets experienced a sharp decline on Wednesday due to global factors. Technical analysis suggests further downside potential for the Nifty index. Several companies like Swiggy and Adani Ports are in focus today. Hyundai Motor India aims to regain its market position with new launches. ONGC is reviewing its Venezuelan…

The Economic Times

Nine More Drugmakers Join the Medicaid Pricing Deals, and the Effect on Your Pharmacy Bill Is Limited

Nine more drugmakers signed most-favored-nation Medicaid pricing deals, bringing the total to 26. Here is what changes and what does not.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Trump Has Now Struck Drug Pricing Deals With 26 Companies. They Cover Nearly 90% Of The Branded Drug Market.

Nine midsize drugmakers joined the White House program and pledged at least $19.6 billion in U.S. manufacturing investments.

International Business Times

Nine New Drugmakers Join Trump's Pricing Pact — But the Savings Remain Unproven

Nine more drugmakers joined Trump's MFN pricing deal, but the discounts flow through Medicaid — a program Texas and Florida never expanded.

Latin Times

Sun Pharma among 9 pharmaceutical firms to lower drug prices for Americans, Trump says

Nine pharmaceutical firms reached deals with the Trump administration for lower drug prices. These agreements expand the total number of companies to twenty-six manufacturers. The deals cover medicines for chronic and rare diseases, benefiting Medicaid programs. Sun Pharma will contribute antibiotics to the US Strategic Active Pharmaceutical Ingredients Reserve. These…

The Economic Times

Stocks in news: Maruti Suzuki, ITC, ZEE, Persistent Systems, and Muthoot Finance

Markets extended their winning streak on Friday, supported by encouraging quarterly business updates. Nifty strengthened its bullish structure by surpassing the 200-day EMA, positioning for further gains. ITC reported a net profit drop while revenue rose, and Maruti Suzuki saw a net profit decline. Sun Pharma reported net profit growth,…

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%

Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, driven by strong performance in India and its innovative medicines business despite weak US formulations sales. EBITDA rose 3% to Rs 4,418 crore.…

The Economic Times

Stocks in news: Maruti Suzuki, ITC, Vedanta, Swiggy, RIL

Indian markets traded in a narrow range, settling marginally higher with mixed cues. Maruti Suzuki, ITC, and Vedanta shares are in focus due to various news developments. Sun Pharma and Bajaj Finserv will announce their first quarter results today. Tata Steel reported a fifteen percent rise in its net profit…

The Economic Times

Indian pharma firms may yet survive Trump's 200% tariff bombshell

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited. India's cost advantage, America's dependence on imported generics and lengthy US factory approval timelines could make large-scale manufacturing shifts difficult despite Trump's…

The Economic Times

200% Trump tariff shock? India’s cheap pills may still beat US rivals

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage may help many drugs remain competitive in the US market, according to the Global Trade Research Initiative (GTRI).

The Economic Times

Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028

Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff plan on imported generic drugs. While generics will remain tariff-free for two years, duties will rise to 100% from August 2028 and 200% from August 2029, weighing…

The Economic Times

Dividend alert! Last day to buy JSW Steel, Sun Pharma, 4 more stocks to earn payouts up to Rs 75

JSW Steel has fixed Tuesday as the record date for its final dividend of Rs 7.1 per share for the financial year 2026. Once approved by the shareholders during its upcoming Annual General Meeting (AGM), the said dividend will be paid within 30 days from the date of its declaration,…

The Economic Times

Stocks in news: HDFC Bank, Vedanta Power, YES Bank, Sun Pharma, Waaree Energies

Indian markets surged for a third straight day, buoyed by global sentiment and strong performance from heavyweight stocks like HDFC Bank and YES Bank. Analysts note a technical breakout, though resistance looms. Several companies, including Dabur India and Vedanta Power, reported positive quarterly updates, while Tata Power withdrew a controversial…

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Bonus issues, stock splits & dividends: Titan, JSW Steel among 49 stocks turning ex-date this week. Do you own any?

Investors must hold shares of these companies in their demat accounts on the record date to be eligible for the respective corporate actions. The list remains tentative, as more companies may announce record dates for dividends, bonus issues and stock splits during the week.

The Economic Times

Market wrap: Sensex falls 372 points, Nifty closes below 23,950; Kotak Mahindra Bank drops 3%

Indian markets ended lower as Sensex and Nifty snapped a two-session winning streak, pressured by geopolitical tensions in the Middle East and broad-based selling. While pharma outperformed, auto stocks dragged. Analysts flagged near-term volatility but maintained a constructive outlook for Nifty above key support levels amid mixed global cues.

The Economic Times

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and consumer healthcare. While US FDA approvals for complex generics remain a challenge, innovation and contract manufacturing offer significant future profit pools. Experts anticipate biosimilars could generate substantial revenue, and despite a slow start, GLP-1…

The Economic Times

Reliance, financials and defence top investment picks as market leadership broadens: Rahul Shah

Reliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant returns. Small banks are also attractive due to improving fundamentals and valuations. While IT valuations are cheap, earnings growth is a concern. Financials, particularly large private banks and NBFCs, remain a…

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGC

Indian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despite this, the broader recovery trend remains intact above 23,700. Several companies like Sun Pharma, Tata Motors, and ONGC are in focus due to significant business developments, including acquisitions,…

The Economic Times

Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transaction

India's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash deal. This strategic move aims to bolster Sun Pharma's product offerings. Innovcare, which markets pharmaceutical drugs, nutraceuticals, and cosmeceuticals, reported steady revenue growth in recent fiscal years. The transaction, expected to…

The Economic Times

Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplash

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic demand and positive global healthcare trends. Analysts see long-term growth potential from aging populations and innovation. Emerging opportunities from supply chain diversification away from China also present a positive outlook for…

The Economic Times

SBI in $1 billion funding for Sun Pharma’s US deal

State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding…

The Economic Times

Sensex falls 70 points, Nifty below 23,900 as US-Iran tensions simmer

Indian stock markets opened lower on Wednesday. Sensex and Nifty saw minor declines. Investors are watching US strikes on Iran and their effect on peace deal hopes. Broader markets are performing better. India VIX, a volatility measure, dropped. Top Sensex losers included HDFC Bank and Infosys. Sun Pharma shares led…

The Economic Times

Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend

Sun Pharma Q4 Results: Profit after tax (PAT) fell 19% sequentially during the quarter under review from Rs 3,369 crore in Q3FY26, while revenue declined 6% from Rs 15,520 crore reported in the October-December quarter of FY26.

The Economic Times

Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future growth for the Indian healthcare sector. Key drivers include AI-led innovation, incremental advancements in niche areas, and improved quality culture. Attractive valuations also support this positive outlook for the…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.